Poland· PL-100426670
Vitrakvi
A larotrectinib product containing larotrectinibum, registered in Poland by Bayer AG. The same ATC class is registered in 2 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Larotrectinib is registered in 2 of 19 countries.
Countries holding a registration under ATC L01XE53 (larotrectinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 1 of them publish a price we can compare per daily dose
Larotrectinib · ATC L01XE53
2 / 19 countries
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Larotrectinibum
- Manufacturer
- Bayer AG
- Country
- Poland (PL)
- ATC code
- L01XE53
- ATC class
- Larotrectinib
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05908229303153
- gtin04057598011792
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
527 interactions on record for larotrectinib.
Graded by severity as the source publishes them — 55 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Larotrectinib · interactions on record
527 records
- 55 severe
- 456 moderate
- 16 minor
Most severe, free to view
- LonafarnibA16AX20severe
- ConivaptanC03XA02severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Larotrectinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesVITRAKVIBayer HealthCare Pharmaceuticals Inc.
- CanadaVITRAKVIBAYER INC
- SwitzerlandVitrakvi 25 mg, KapselnBayer (Schweiz) AG
- CzechiaVITRAKVIBayer AG, Leverkusen
- SpainVITRAKVI 25 MG CAPSULAS DURASBayer Ag
- FinlandVITRAKVIBayer AG
- BelgiumVitrakvi 25 mgBayer
- United KingdomVitrakvi 25mg capsulesBayer Plc
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vitrakvi
- Liechtenstein · Vitrakvi
- Norway · Vitrakvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/03a59853-970b-4d4c-b36d-00e8d7ba681a GET /v1/drugs/03a59853-970b-4d4c-b36d-00e8d7ba681a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "25 mg",
"packaging": "05908229303153 ¦ Rp ¦ Skasowane ¦ EU/1/19/1385/001 ¦ 134368\n56 kaps.\n04057598011792 ¦ Rp ¦ EU/1/19/1385/001 ¦ 138980\n1 butelka 56 kaps.",
"substance": "Larotrectinibum 25 mg",
"common_name": "Larotrectinibum",
"pl_product_id": "100426670",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about larotrectinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.